LDL cholesterol lowering in CKD looks SHARP

While the cardiovascular benefits of LDL cholesterol lowering in patients without kidney disease are well established, the effects on people with moderate to severe kidney disease has remained unproven. The SHARP (Study of Heart and Renal Protection) study was a randomised double-blind trial that included 9270 patients with chronic kidney disease (3023 of whom were […]

Read More…

Ezetimibe and Cancer: What is the risk?

The recent Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) Trial showed that the combined treatment had no impact on the progression of aortic stenosis – but an excess of incident cancers was identified in the simvastatin-ezetimibe group when compared to placebo (105 vs 70, p=0.01). Deaths from cancer were also more frequent in the simvastatin-ezetimibe […]

Read More…

SEAS apart: no role for lipid lowering in aortic valve disease

Calcific aortic stenosis shares risk factors with coronary heart disease and predicts death and MI without the need for large gradients.¬† Hyperlipidaemia has been suggested as a risk factor for the development of aortic stenosis but to date lipid lowering studies have demonstrated conflicting results. […]

Read More…